Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene

ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene

US Patent 11780925 · Granted Oct 10, 2023

Assignee

No assignee recorded.

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Bispecific antibody2025
Generation of binding molecules2025
Generation of binding molecules2025
ERBB-2 and ERBB-3 binding bispecific antibodies for use in the treatment of cell2025
ERBB-2 and ERBB-3 binding bispecific antibodies for use in the treatment of cell2025
ERBB-2 and ERBB-3 binding bispecific antibodies for use in the treatment of cell2025
ERBB-2 and ERBB-3 binding bispecific antibodies for use in the treatment of cell2025
Combination of an ErbB-2/ErbB-3 bispecific antibody with endocrine therapy for b2025
Combination of an ErbB-2/ErbB-3 bispecific antibody with endocrine therapy for b2025
Antibody that binds ErbB-2 and ErbB-32024
Antibody that binds ErbB-2 and ErbB-32024
Antibody that binds ErbB-2 and ErbB-32024